| scholarly article | Q13442814 |
| P50 | author | Matthias Cavassini | Q30004177 |
| Swiss HIV Cohort Study | Q33121558 | ||
| P2093 | author name string | Heiner C Bucher | |
| Bernard Hirschel | |||
| Andri Rauch | |||
| Mathew Simcock | |||
| Luigia Elzi | |||
| Christoph A Fux | |||
| Pietro Vernazza | |||
| Hansjakob Furrer | |||
| Enos Bernasconi | |||
| Milos Opravil | |||
| P433 | issue | 8 | |
| P921 | main subject | HIV | Q15787 |
| tenofovir | Q155954 | ||
| P304 | page(s) | 1077-1082 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Antiviral Therapy | Q4775353 |
| P1476 | title | Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study | |
| P478 | volume | 13 |
| Q35003539 | AIDS vaccines and preexposure prophylaxis: is synergy possible? |
| Q34160511 | Aging, human immunodeficiency virus, and bone health |
| Q95785042 | An intrinsic way of multiclassification of endogenous psychoses. A follow-through investigation/Budapest 2000/based upon Leonhard's classification |
| Q43055326 | Antiretroviral therapy and adverse skeletal effects |
| Q37263395 | Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? |
| Q93079405 | Bone Diseases in Patients with Chronic Liver Disease |
| Q35019051 | Bone disease in HIV infection: a practical review and recommendations for HIV care providers |
| Q38792298 | Bone health and HIV in resource-limited settings: a scoping review |
| Q35000905 | Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o |
| Q37272765 | Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy |
| Q36128333 | Care of the human immunodeficiency virus-infected menopausal woman |
| Q37182852 | Differences in Serum Levels of Magnesium, Phosphate, and Albumin for HAART-Experienced and HAART-Naïve Female Patients Attending Parirenyatwa Opportunistic Infections Clinic in Harare, Zimbabwe |
| Q34409132 | Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B. |
| Q37196931 | Elevation in Serum Concentration of Bone-Specific Alkaline Phosphatase without Elevation in Serum Creatinine Concentration Secondary to Adefovir Dipivoxil Therapy in Chronic Hepatitis B Virus Infection |
| Q35102114 | Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIV |
| Q92730901 | Kidney Disease in HIV Infection |
| Q35827917 | Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir. |
| Q26772852 | Perspectives on menopause and women with HIV |
| Q34952127 | Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial |
| Q33635034 | Tenofovir-associated bone density loss |
| Q37838799 | The Rapidly Evolving Research on Vitamin D Among HIV-Infected Populations |
| Q37354871 | The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis |
| Q38033446 | Update on tenofovir toxicity in the kidney |
| Q35019046 | Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women |
| Q35815286 | Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial |
Search more.